Clinical trials: Overactive Bladder (OAB)
Overactive Bladder, Urinary Incontinence
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment…
- Trial name
- NCT00439192
- Testing
- ELB245, Tolterodine
- Where
- 31 sites in Germany, Poland and 1 more
- Volunteers
- 275 people
- Sponsor
- elbion AG
Overactive Bladder (OAB)
Detrol LA In Men With Overactive Bladder.
An interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and…
- Trial name
- NCT00282932
- Testing
- Detrol LA
- Where
- 81 sites in United States, Canada and 13 more
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
To evaluate the safety and efficacy of SSR240600C versus placebo on clinical and cystometric parameters in patients with OAB and UUI.
- Trial name
- NCT00174798
- Testing
- SSR240600C, Tolterodine
- Where
- 22 sites in United States
- Volunteers
- 118 people
- Sponsor
- Sanofi
Overactive Bladder
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
A prospective, multicenter, observation study to estimate the dry mouth in OAB patients with solifenacin
- Trial name
- OAB (NCT01437670)
- Testing
- solifenacin 5mg, 10mg
- Where
- South Korea
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Overactive Bladder, Urinary Incontinence
Surface Nerve Stimulation Treatment for OAB in Children
The purpose of this study is to perform a randomized controlled investigation of the effect of surface nerve stimulation on functional daytime incontinence in children with OAB.
- Trial name
- NCT00282490
- Testing
- Nerve stimulator
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Overactive Bladder Syndrome
Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder
This study has 2 parts. Part 1 is a 12-week observational study of weekly Posterior Tibial Nerve Stimulation (PTNS) treatment for women with overactive bladder.
- Trial name
- NCT00912314
- Testing
- PTNS
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Diego
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Multiple Sclerosis, Overactive Bladder
PTNS for Female Patients Suffering From Multiple Sclerosis
This is a pilot, single blind, randomized, sham-controlled trial to assess the benefit of Percutaneous Tibial Nerve Stimulation (PTNS) in treating bladder overactivity (OAB) symptoms in multiple sclerosis (MS) patients.
- Trial name
- PTNS-MS (NCT05422625)
- Testing
- PTNS Treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Corewell Health East
Overactive Bladder
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
This extension trial of SP668 consists of two phases: double-blind treatment and open-label extension. The trial provides subjects the option of long-term treatment with sustained release (SR) fesoterodine (SPM 907) and to assess…
- Trial name
- NCT00220389
- Testing
- SPM 907
- Where
- United States
- Sponsor
- Pfizer
Overactive Bladder (OAB)
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
The purpose of this study is to track changes in overactive bladder (OAB) medical regimen and/or OAB medication dosage requirements.
- Trial name
- NCT01317810
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
- Trial name
- NCT00444925
- Testing
- fesoterodine fumarate, tolterodine tartrate
- Where
- 178 sites in United States, Belgium and 27 more
- Volunteers
- 1,712 people
- Sponsor
- Pfizer
Overactive Bladder
Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)
The aim of the study is to determine how well the drug BAY1817080 works in OAB patients with urgency urinary incontinence (UUI), defined as involuntary leakage of urine, accompanied or immediately preceded by a sudden compelling…
- Trial name
- OVADER (NCT04545580)
- Testing
- BAY1817080
- Where
- 28 sites in Australia, Austria and 7 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Overactive Bladder
Bacterial Genomic Sequencing in Overactive Bladder
No one really knows what causes overactive bladder syndrome (OAB). Urinary tract infection (UTI)causes similar symptoms to OAB with the difference being the presence of bacteria, as evidenced by routine microbiology cultures.
- Trial name
- NCT01642277
- Testing
- Solifenacin
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Loyola University
Overactive Bladder (OAB), Urinary Urgency
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women…
- Conditions
- Overactive Bladder (OAB), Urinary Urgency, Urinary Urge Incontinence (UUI), Nocturia
- Trial name
- APPROVE (NCT06797245)
- Testing
- RiSolve App, AUGS Patient Handouts
- Where
- 10 sites in United States
- Volunteers
- 596 people
- Sponsor
- Medstar Health Research Institute
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Bladder, Overactive
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB).
- Trial name
- NCT01314872
- Testing
- Vibegron, Tolterodine ER
- Volunteers
- 1,395 people
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder (OAB), Incontinence, Urge
Efficacy and Safety of 7 Millimeters Vaginal Radiofrequency in Overactive Bladder
The investigator hypothesizes that controlled delivery of low heat (45-50 Centigrade) to the sub-detrusor and detrusor muscle can ablate the autonomic nerve endings and control overactive bladder symptoms without causing…
- Trial name
- HYPNOS (NCT07279142)
- Testing
- Radiofrequency
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- IRCCS San Raffaele
Overactive Bladder, Diversity
Diversity in Patients With OAB
An overactive bladder (OAB) is a condition characterized by frequent en nightly voiding, small bladder capacity and the occurrence of sudden urge to void, with or without urinary incontinence.
- Conditions
- Overactive Bladder, Diversity, Onabotulinum Toxin A, Sacral Neuromodulation
- Trial name
- DOAB (NCT05903105)
- Testing
- Questionnaires
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Ghent
Overactive Bladder (OAB), Refractory Overactive Bladder
Cefar URO - Symptomatic Treatment of Overactive Bladder
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the…
- Conditions
- Overactive Bladder (OAB), Refractory Overactive Bladder, Urinary Urgency and Frequency
- Trial name
- NCT06659536
- Testing
- Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
- Where
- France
- Volunteers
- 53 people
- Sponsor
- DJO UK Ltd
Bladder Pain Syndrome, Interstitial Cystitis
Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis
To identify new, simple and reliable biomarkers for bladder pain syndrome/interstitial cystitis (BPS/IC) for diagnosis of this disease.
- Conditions
- Bladder Pain Syndrome, Interstitial Cystitis, Overactive Bladder
- Trial name
- NCT03023241
- Testing
- biopsy
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Cantonal Hospital, Frauenfeld